India’s Next Pharmaceutical Advantage Will Be the Ability to Develop, Not Just Manufacture
November 11, 2026

India has earned global recognition as a reliable pharmaceutical manufacturing base. Scale, cost competitiveness, scientific talent and a long record of supplying quality medicines to diverse markets have made the industry integral to global healthcare. That base remains a national strength, and it is not going away. It is also, on its own, a ceiling, writes Aniel Khubchandani, CEO, Small Molecules – CDMO, Aragen Life Sciences.
India ranks third in the world in pharmaceutical production by volume but eleventh by value [1]. Median Research and Development (R&D) intensity among Indian pharmaceutical companies is 5.8 percent of revenue, against 17.3 per cent globally [2]. We manufacture at global scale and develop at a third of the global rate.
Scale alone is no longer the differentiator. As pipelines grow more complex, the customer needs a partner that can solve development problems early, from route selection and formulation design to analytical development and scale-up. A molecule can perform well in the laboratory and then meet impurity control, process safety or raw material constraints later. Found late, each costs a development cycle.

Process development redesigns the problem rather than managing it. Many small-molecule routes depend on a hazardous step, a nitration or a diazotization, that is routine in a flask and difficult at several hundred kilograms. Work in organic process Research & Development on a key Osimertinib building block ran that sequence continuously at a 16-minute residence time and 98 per cent yield [3]. Only a small volume reacts at any moment, changing the safety case and the cost of capacity. Molecules entering development are also more potent and more structurally complex, and complexity of that kind has to be designed for, not absorbed at the manufacturing stage.
A Contract Research, Development and Manufacturing Organization (CRDMO) replaces handovers with continuity. Demand is moving the same way: the IQVIA Institute reports that emerging biopharma companies now account for “70 per cent of all clinical-stage assets in the industry pipeline”, most of them unpartnered [4]. Science-rich and infrastructure-light, they need a partner who can carry a molecule from route scouting to GMP supply.
For Indian CRDMOs, that means entering customer programs earlier and contributing to the science, rather than joining once a product is ready to be made. The differentiator is no longer capacity, but scientific expertise, development experience and manufacturing execution held around one program.
Integration as a Competitive Advantage
A process that works at laboratory scale is not automatically safe or economical at commercial scale, and the larger prize sits where drug substance and drug product development meet. A polymorph chosen for crystallization behavior in the active pharmaceutical ingredient (API) plant may not give the best dissolution or stability in the finished dose.
Handled in sequence by separate organizations, each becomes rework. Handled together while all are still changeable, crystallization, formulation strategy, analytical control and the manufacturing process align once. That is where program time is genuinely recovered.
Speed is Where the Advantage becomes Measurable
Development capability stays abstract until it shows up as time. Some of it is now statutory: the New Drugs and Clinical Trials Rules, 2019 set a 30-working day decision timeline for trial applications for a new drug discovered in India, deemed approved if no communication follows [5]. A January 2026 amendment cut the test license timeline from 90 to 45 working days [6].
Some is peer reviewed, and Indian. Scientists at CSIR Indian Institute of Chemical Technology, Hyderabad reported in Chemical Communications a “continuous flow ultra-fast daclatasvir synthesis in 33.2 min”, against a batch route constrained by production times of three to ten days [7]. A published process, from a public Indian laboratory.
Some needs care. Nature Biotechnology reported a preclinical candidate nominated in roughly 18 months using generative methods, but a Drug Discovery Today analysis found AI-discovered molecules succeed 80–90% in Phase I and nearer 40% in Phase II [8, 9]. Computation is compressing the front end of discovery, not clinical attrition.
Building the next layer of trust
Scientific capability alone will not move India up the value chain. Trust will: quality systems, data integrity, regulatory discipline and people able to work across sophisticated technology. Scrutiny is structural now, with most US Food and Drug Administration drug quality inspections conducted at foreign sites [10].
A partner is judged on how a quality system behaves when something goes wrong, and on something discussed far less: supply reliability. Policy is now backing that build. The Promotion of Research and Innovation in Pharma MedTech (PRIP) scheme carries an outlay of ₹5,000 crore, and the Research Development and Innovation scheme approved in July 2025 establishes a ₹1 lakh crore corpus [11]. Money, though, is the easier part. The harder work is translational depth: molecules originated in India remain few, and the doctoral pipeline has to deepen in process chemistry, crystallization and analytical science.
India holds the foundations: manufacturing depth, scientific talent and growing research capability. Connecting them is the task. The future of Indian pharma will not be defined by how much it can manufacture, but by how well it can develop, solve and deliver, and by how much of the value between discovery and commercialization it captures. In every molecule is the possibility for better health; the question is how much of it India develops itself.
References
[1] India Brand Equity Foundation (IBEF), Pharmaceutical Exports from India, 2025.
[2] FAST-India, State of Industry R&D in India, May 2024.
[3] Organic Process Research & Development, 2020. DOI: 10.1021/acs.oprd.0c00254
[4] IQVIA Institute for Human Data Science, Biopharma M&A: Outlook for 2026, January 2026.
[5] New Drugs and Clinical Trials Rules, 2019, Central Drugs Standard Control Organisation (CDSCO).
[6] New Drugs and Clinical Trials (Amendment) Rules, 2026, G.S.R. 46(E), 20 January 2026.
[7] Chemical Communications, 2019, 55(79), 11852–11855. DOI: 10.1039/C9CC06127D
[8] Nature Biotechnology, 2024. DOI: 10.1038/s41587-024-02143-0
[9] Drug Discovery Today, 2024, 29(6), 104009. DOI: 10.1016/j. drudis.2024.104009
[10] US Food and Drug Administration, FY2024 drug quality assurance inspection reporting.
[11] Press Information Bureau: PRIP scheme; Cabinet approval of the Research Development and Innovation scheme, 1 July 2025.
Source – PharmaBio World